CG Oncology, Inc. Capital Expenditures
CG Oncology, Inc. (CGON) reported Capital Expenditures of $772.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- CG Oncology, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $468.00K, a 3242.86% increase year-over-year.
- CG Oncology, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $304.00K, a 1800.00% increase year-over-year.
- CG Oncology, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $7.00K, a 96.65% decline year-over-year.
- CG Oncology, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $97.00K.
- CG Oncology, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $134.00K, a 42.74% decline from fiscal 2024.
- CG Oncology, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $234.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $468.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $772.00K 10-Q · filed 2026-08-06 | $779.00K derived: sum of 3 quarters · filed 2026-08-06 | $876.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $304.00K 10-Q · filed 2026-05-08 | $311.00K derived: sum of 2 quarters · filed 2026-05-08 | $408.00K derived: sum of 3 quarters · filed 2026-05-08 | $422.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $104.00K derived: sum of 2 quarters · filed 2026-02-27 | $118.00K derived: sum of 3 quarters · filed 2026-08-06 | $134.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $111.00K derived: sum of 2 quarters · filed 2026-08-06 | $127.00K 10-Q · filed 2025-11-14 | $336.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $30.00K 10-Q · filed 2026-08-06 | $239.00K derived: sum of 3 quarters · filed 2026-08-06 | $238.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $16.00K 10-Q · filed 2026-05-08 | $225.00K derived: sum of 2 quarters · filed 2026-05-08 | $224.00K derived: sum of 3 quarters · filed 2026-05-08 | $238.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $208.00K derived: sum of 2 quarters · filed 2026-02-27 | $222.00K derived: sum of 3 quarters · filed 2026-02-27 | $234.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $13.00K derived: sum of 2 quarters · filed 2025-11-14 | $25.00K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $26.00K 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $12.00K 10-Q · filed 2025-05-13 | |||
| 2023-06-30 | $6.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |